Liquidia CFO Michael Kaseta Takes On Additional Role Of COO
(RTTNews) - Biopharmaceutical company Liquidia Corp. (LQDA) announced Friday updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA (treprostinil) inhalation powder.
Michael Kaseta, Chief Financial Officer (CFO), has added the role of Chief Operating Officer (COO) to his responsibilities effective on January 15, 2023.
In his expanded role as COO/CFO, Kaseta will be responsible for several key areas in addition to finance, including human resources, information technology, quality, manufacturing, and business strategy.
In connection with this change, Michael Hunter was also promoted to Senior Vice President of Manufacturing Operations, where he will manage all day-to-day manufacturing and supply chain operations internally and externally.
Simultaneously, former Chief Operations Officer, Robert Lippe, will transition out of the Company over a three-month period.
Liquidia Says Court Denies United Therapeutics' Motion For Injunction To Block Launch Of YUTREPIA
Swiss Franc Rises Against Most Majors
Canadian Market Stays Firm After Hitting New Record High
Canadian Dollar Firms Against Majors
Swiss Market Ends Sharply Lower On Weak Global Cues
European Stocks Tumble On Economic, Geopolitical Concerns
Bay Street Likely To Open On Mixed Note
